<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02705963</url>
  </required_header>
  <id_info>
    <org_study_id>CTMT212X2102</org_study_id>
    <nct_id>NCT02705963</nct_id>
  </id_info>
  <brief_title>A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors</brief_title>
  <official_title>A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of trametinib once daily on the&#xD;
      pharmacokinetics (PK) of a daily dosing oral contraceptives (OCs) containing norethindrone&#xD;
      (NE) and ethinyl estradiol (EE) in female patients with solid tumors. The PK of trametinib&#xD;
      and its metabolite M5 will also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2016</start_date>
  <completion_date type="Actual">August 29, 2019</completion_date>
  <primary_completion_date type="Actual">August 29, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics parameter: AUCtau of NE and EE alone and in combination with trametinib</measure>
    <time_frame>Day 5 and 6 and 21 and 22</time_frame>
    <description>To evaluate the effect of multiple doses of trametinib (2 mg once daily) on the steady state pharmacokinetics of combination OC (NE and EE) in female patients with solid tumors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameter: AUClast of NE and EE alone and in combination with trametinib</measure>
    <time_frame>Day 5 and 6 and 21 and 22</time_frame>
    <description>To evaluate the effect of multiple doses of trametinib (2 mg once daily) on the steady state pharmacokinetics of combination OC (NE and EE) in female patients with solid tumors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameter: Cmax of NE and EE alone and in combination with trametinib</measure>
    <time_frame>Day 5 and 6 and 21 and 22</time_frame>
    <description>To evaluate the effect of multiple doses of trametinib (2 mg once daily) on the steady state pharmacokinetics of combination OC (NE and EE) in female patients with solid tumors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameter: Tmax of NE and EE alone and incombination with trametinib</measure>
    <time_frame>Days 5 and 6 and 21 and 22</time_frame>
    <description>To evaluate the effect of multiple doses of trametinib (2 mg once daily) on the steady state pharmacokinetics of combination OC (NE and EE) in female patients with solid tumors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter: AUClast of M5</measure>
    <time_frame>Day 21 and 22</time_frame>
    <description>Characterize PK of metabolite M5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter: AUCtau of M5</measure>
    <time_frame>Day 21 and 22</time_frame>
    <description>Characterize PK of metabolite M5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter: Cmax of M5</measure>
    <time_frame>Day 21 and 22</time_frame>
    <description>Characterize PK of metabolite M5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter: Tmax of M5</measure>
    <time_frame>Day 21 and 22</time_frame>
    <description>Characterize PK of metabolite M5</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Oral Contraceptive / Trametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In treatment period 1 of the PK Phase patients will take the Oral Contraceptive once daily from Days 1-5. Period 2 of the PK Phase starts on Day 6 when patients take both the Oral Contraceptive and trametinib once daily from Days 6 to 21. Patients may continue dosing with trametinib only once daily from Day 22 onwards (post PK Phase).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Each tablet is 2mg trametinib to be taken orally once daily.</description>
    <arm_group_label>Oral Contraceptive / Trametinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Each tablet is 0.5mg trametinib to be taken orally once daily. 0.5mg tablets may be used if a dose reduction is required.</description>
    <arm_group_label>Oral Contraceptive / Trametinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)</intervention_name>
    <description>Combined oral contraceptive to be taken orally once daily.</description>
    <arm_group_label>Oral Contraceptive / Trametinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a histologically or cytologically confirmed diagnosis of a solid tumor malignancy&#xD;
             (except for any excluded malignancies listed in the Exclusion Criteria) that is not&#xD;
             responsive to standard therapy(ies) or for which there is no approved therapy.&#xD;
&#xD;
          -  Meets one of the following criteria: Is currently on a stable regimen of an oral&#xD;
             contraceptive containing 1mg NE and 0.035mg EE, or Is willing to switch to a regimen&#xD;
             of an oral contraceptive containing 1mg NE and 0.035mg EE from a stable regimen of an&#xD;
             alternate OC, or Is willing to start a regimen of an oral contraceptive containing 1mg&#xD;
             NE and 0.035mg EE.&#xD;
&#xD;
          -  Meets one of the following criteria: Is post-menopausal, or, Women of child-bearing&#xD;
             potential, defined as all women physiologically capable of becoming pregnant, must use&#xD;
             highly effective methods of contraception during dosing and for four months after&#xD;
             stopping medication.&#xD;
&#xD;
          -  Has no prior treatment-related toxicities &gt;Grade 1 (except alopecia) at the time of&#xD;
             enrolment.&#xD;
&#xD;
          -  Patient must meet the following laboratory values at the screening visit: Absolute&#xD;
             Neutrophil Count ≥1.5 x 109/L. Platelets ≥75 x 109/L. Hemoglobin (Hgb) ≥9 g/dL. Serum&#xD;
             creatinine &lt;1.5 mg/dL. Total bilirubin ≤1.5 x upper limit of normal (ULN) (isolated&#xD;
             bilirubin &gt;1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin&#xD;
             &lt;35%). Aspartate transaminase (AST) ≤ 3.0 x ULN, except for patients with liver&#xD;
             metastasis, who may only be included if AST ≤5.0 x ULN. Alanine transaminase (ALT) ≤&#xD;
             3.0 x ULN, except for patients with liver metastasis or tumor infiltration, who may&#xD;
             only be included if ALT ≤5.0 x ULN. Prothrombin time (PT)/International normalized&#xD;
             ratio (INR) and Partial thromboplastin time (PTT) ≤1.5xULN. Note: patients receiving&#xD;
             therapeutic anticoagulation agents prior screening are permitted. Albumin 2.5 g/dL.&#xD;
&#xD;
          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0-1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or current diagnosis of cardiac disease indicating significant risk of safety&#xD;
             for patients participating in the study such as uncontrolled or significant cardiac&#xD;
             disease&#xD;
&#xD;
          -  Has had any major surgery, extensive radiotherapy, or anti-cancer therapy (e.g.,&#xD;
             chemotherapy with delayed toxicity, biologic therapy, or immunotherapy) within 21 days&#xD;
             prior to enrolment and/or daily or weekly chemotherapy without the potential for&#xD;
             delayed toxicity within 14 days prior to enrolment. Prolonged immobilization must have&#xD;
             resolved prior to enrolment.&#xD;
&#xD;
          -  Has a known or suspected carcinoma that is excluded as administration of Oral&#xD;
             Contraceptive would be contraindicated.&#xD;
&#xD;
          -  Has a history of another malignancy.&#xD;
&#xD;
          -  Has a history of interstitial lung disease or pneumonitis.&#xD;
&#xD;
          -  Has a history of RVO.&#xD;
&#xD;
          -  Has a history of any of conditions that would contraindicate administration of an OC&#xD;
&#xD;
          -  Has symptomatic or untreated leptomeningeal, brain metastases, or spinal cord&#xD;
             compression.&#xD;
&#xD;
        Other protocol-defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karmanos Cancer Institute Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17699</url>
    <description>Results for CTMT212X2102 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <link>
    <url>https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=612</url>
    <description>A Plain Language Trial Summary is available on novartisclinicaltrials.com</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2016</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone Acetate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

